Fig. 2

Validation of the prognostic value of eight cytokines in the aNSCLC validation cohort (n = 109) and performance of CD14 in predicting PFS in the dynamic cohort and mIF cohort (n = 21). (A) Kaplan-Meier curve for PFS based on CD14 expression. (B-C) Correlation between the eight cytokines and lymphocyte subsets, including CD3⁺ T (total T) cells, CD3⁺CD4⁺ T (Th) cells, CD3⁺CD8⁺ T (Ts) cells, CD3⁻CD16⁺CD56⁺ (NK) cells, and CD3⁻CD19⁺ (B) cells. (D) Kaplan-Meier analysis of PFS based on CD14 intensity. (E) Representative mIF staining of DAPI, CD14, and pan Cytokeratin in patient #1 with short PFS (106 days) and patient #2 with long PFS (511 days). (Abbreviation: aNSCLC: advanced non-small cell lung cancer; PFS: progression free survival; mIF: multiple immunofluorescence; Mann-Whitney test was performed between groups)